{
  "docId": "019de075-079f-70cb-9742-824e65eea6f3",
  "docSlug": "a0089ddc1a521dbfdcfb284bc86531b7",
  "documentTitle": "OmniAb | Results Presentation Deck | 17 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 17,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-079f-70cb-9742-824e65eea6f3/8",
  "deckHref": "/decks/019de075-079f-70cb-9742-824e65eea6f3",
  "deckJsonHref": "/decks/019de075-079f-70cb-9742-824e65eea6f3.json",
  "deckAnchorHref": "/decks/019de075-079f-70cb-9742-824e65eea6f3#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.1,
        "y": 0.45
      },
      "kind": "list",
      "text": "Batoclimab: Ongoing studies in Myasthenia Gravis (P3), Thyroid Eye Disease (P3), Chronic Inflammatory Demyelinating Polyneuropathy (P2b), Graves' Disease (P2)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "681f8166-7940-475f-a889-056854246876",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.66,
        "y": 0.45
      },
      "kind": "list",
      "text": "SGN-BB228: Investigational costimulatory bispecific molecule; Phase 1 study now enrolling in advanced melanoma and other solid tumors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83caf719-c780-4d06-8eb9-94d056dd9537",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.38,
        "y": 0.45
      },
      "kind": "list",
      "text": "IMVT-1402: Next-gen FcRn antagonist; Immunovant expects SAD/MAD Phase 1 data in second half of 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bfd0c18d-bc2d-4dc2-862c-2614c95ba8ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.04,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Reference: Partner and Company disclosures",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a76cf1ae-18cf-4658-afd9-b2609e1a18b8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "title",
      "text": "SELECT RECENT DEVELOPMENTS SHOW CONTINUED PARTNER MOMENTUM",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d48086de-4f2a-4389-962e-b923b9c0c54d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Q1 2023 and Recent Updates",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73ddc99f-75dc-47fe-a853-e9ee31a2e72e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "d4c7d060-58e2-4a48-a9d1-8e7e13f82b1e",
      "evidence": "list/bullet: Batoclimab: Ongoing studies in Myasthenia Gravis (P3), Thyroid Eye Disease (P3), Chronic Inflammatory Demyelinating Polyneuropathy (P2b), Graves' Disease (P2)",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 5,
      "beatId": "5f4bee5d-76a4-4f08-9b57-0eeb6b07208b",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "What Is",
      "beatSlug": "sparkline-what-is-3",
      "evidence": "Slides 5-8 provide more details on the company's partners and recent developments.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 8,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "28815665-4668-4824-a4e0-39400a75e6c3",
      "evidence": "The presentation emphasizes the significance of new clinical entrants and partner momentum.",
      "position": 0,
      "objective": "Highlighting the importance of partner momentum",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}